SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs India informs about board meeting

07 Aug 2025 Evaluate
Kilitch Drugs India has informed that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2025.

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

135.10 4.55 (3.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×